Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evning Exposure to Computer Screen Disrupts Sleep, Attention and Biological Rhythms

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02957383
Recruitment Status : Completed
First Posted : November 7, 2016
Last Update Posted : November 8, 2016
Sponsor:
Information provided by (Responsible Party):
Lilach Kemer, Assuta Medical Center

Brief Summary:

Light exposure is on the rise in recent years. In large part because of unintentional illumination from screens that emit light directly into the eyes. Millions of computers, tablets, televisions, and smart-phones are sold worldwide every month and the usage time of these devices is increasing constantly. Today, people are exposed to ongoing light exposure from these device screens, emitting short wave length (SWL) during day and night hours, whether as active or passive users. In sum, artificial light at night (ALAN) seem to affect human circadian rhythmicity (melatonin and thermoregulation) and sleep, with two major factors. First, wavelength of light, with SWL being most detrimental to sleep and rhythms, when compared to LWL (Brianard et al., 2001). Second, a dose-response relationship exists between increasing light intensity and poorer sleep/circadian rhythms (Brianard et al., 1988; West et al., 2011).

Based on existing knowledge, we hypothesize that when compared to long wavelength LWL illumination, short wavelength SWL illumination from computer screen will have a more damaging effect on melatonin (MLT) production and secretion, interfering body temperature regulation and affecting sleep quality, efficiency and sleep architecture. In addition, we hypothesized that intensity of the screen illumination will play another important factor on these outcomes, we assume that high intensity compared to low intensity will have more damaging effect on: melatonin, thermoregulation and sleep.


Condition or disease Intervention/treatment Phase
Sleep Disorder Other: Wavelength Other: Intensity Not Applicable

  Show Detailed Description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 19 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Single (Participant)
Primary Purpose: Basic Science
Official Title: Evning Exposure to Computer Screen Disrupts Sleep, Attention and Biological Rhythms
Study Start Date : July 2015
Actual Primary Completion Date : March 2016
Actual Study Completion Date : August 2016

Arm Intervention/treatment
Experimental: wavelength
Wavelength at two levels: short (SWL)-485 nm (13500k) and long (LWL)-620 nm (4250k)
Other: Wavelength
wavelength at two levels: short (SWL)-485 nm (13500k) and long (LWL)-620 nm (4250k)

Other: Intensity
Luminance at two levels: low - 80 lux (35mw/cm2) and high - 350 lux (160mw/cm2

Experimental: intensity
Luminance at two levels: low - 80 lux (35mw/cm2) and high - 350 lux (160mw/cm2).
Other: Wavelength
wavelength at two levels: short (SWL)-485 nm (13500k) and long (LWL)-620 nm (4250k)

Other: Intensity
Luminance at two levels: low - 80 lux (35mw/cm2) and high - 350 lux (160mw/cm2




Primary Outcome Measures :
  1. Body temperature [ Time Frame: 12 hours ]
    Oral body temperature, physiological marker

  2. Melatonin secretion [ Time Frame: 12 hours ]
    Melatonin - Sulfate Urine ELISA 6-SMT ng/ml, physiological marker

  3. Epworth Sleepiness Scale (ESS) questionire- Sleepiness [ Time Frame: 1 day ]
    Epworth Sleepiness Scale (ESS) questionire score- Number

  4. Brief Symptom Inventory (BSI)- questionaire [ Time Frame: 1 day ]
    Assess the subjects emotional state- number

  5. Karolinska Sleep Questionnaire (KSS)-Subjective sleepiness [ Time Frame: 1 day ]
    KSS questionaire - number

  6. Attention [ Time Frame: 1hour ]
    continuous performance test (CPT-III) a computerized attention and concentration test. number

  7. Total Sleep Time [ Time Frame: 1 night ]
    Total sleep time in minute. physiological marker

  8. sleep efficiency [ Time Frame: 1 night ]
    Percentage of sleep efficiency , physiological marker

  9. Sleep latency to stage 1 [ Time Frame: 1 night ]
    Tine in minute to sleep stage 1, physiological marker

  10. Sleep latency to stage 2 [ Time Frame: 1 night ]
    Tine in minute to sleep stage 2, physiological marker

  11. Wake% TIB [ Time Frame: 1 night ]
    Percentage of wake from time in bed, physiological marker

  12. Stage 1% TIB [ Time Frame: 1 night ]
    Percentage of sleep stage 1 from time in bed, physiological marker

  13. Stage 2% TIB [ Time Frame: 1 night ]
    Percentage of sleep stage 2 from time in bed, physiological marker

  14. SWS% TIB [ Time Frame: 1 night ]
    Percentage of sleep stage SWS from time in bed, physiological marker



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • regular sleep habits in Pittsburgh Sleep Quality Index (PSQI) questionnaire index<5 normative sleep-wake cycle type (Horne-Ostberg morningness-eveningness questionnaire) 6-8 hours of sleep, normative sleep patterns, and no sleep/wake schedule.

Exclusion Criteria:

  • participants with ocular damage, such as to their field of vision, color blindness, or impaired functioning of the pupil in reaction to light were excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02957383


Sponsors and Collaborators
Assuta Medical Center
Investigators
Layout table for investigator information
Principal Investigator: Lilach Kemer, Dr Assuta Medical Center

Layout table for additonal information
Responsible Party: Lilach Kemer, Dr. Lilach Kemer, Assuta Medical Center
ClinicalTrials.gov Identifier: NCT02957383     History of Changes
Other Study ID Numbers: 2014068
First Posted: November 7, 2016    Key Record Dates
Last Update Posted: November 8, 2016
Last Verified: November 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Lilach Kemer, Assuta Medical Center:
Sleep, Melatonin
Circadian Rhythm
Temperature
screen illumination
Additional relevant MeSH terms:
Layout table for MeSH terms
Sleep Wake Disorders
Nervous System Diseases
Neurologic Manifestations
Signs and Symptoms
Mental Disorders